UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Precision oncology: origins, optimism, and potential

The lancet oncology, 2016-02, Vol.17 (2), p.e81-e86

2016

Volltextzugriff (PDF)

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib

Seminars in oncology, 2017-12, Vol.44 (6), p.395-403

2017

Volltextzugriff (PDF)

Cancer Drugs in the United States: Justum Pretium—The Just Price

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3600-3604

2013

Volltextzugriff (PDF)

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?

Clinical cancer research, 2010-12, Vol.16 (24), p.5972-5980

2010

Volltextzugriff (PDF)

Precision Oncology: A Strategy we were not Ready to Deploy

Seminars in oncology, 2016-02, Vol.43 (1), p.9-12

2016

Volltextzugriff (PDF)

Strategies for reversing drug resistance

Oncogene, 2003-10, Vol.22 (47), p.7512-7523

2003

Volltextzugriff (PDF)

Gefitinib and Erlotinib in Metastatic Non‐Small Cell Lung Cancer: A Meta‐Analysis of Toxicity and Efficacy of Randomized Clinical Trials

The oncologist (Dayton, Ohio), 2015-04, Vol.20 (4), p.400-410

2015

Volltextzugriff (PDF)

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Blood, 2011-06, Vol.117 (22), p.5827-5834

2011

Volltextzugriff (PDF)

Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?

Clinical cancer research, 2007-12, Vol.13 (24), p.7280-7287

2007

Volltextzugriff (PDF)

Mechanisms of resistance to PARP inhibitors--three and counting

Cancer discovery, 2013-01, Vol.3 (1), p.20-23

2013

Volltextzugriff (PDF)

Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia

The New England journal of medicine, 2012-09, Vol.367 (10), p.922-930

2012

Volltextzugriff (PDF)

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Journal of clinical oncology, 2009-11, Vol.27 (32), p.5410-5417

2009

Volltextzugriff (PDF)

Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4619-4629

2009

Volltextzugriff (PDF)

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

The New England journal of medicine, 2012-06, Vol.366 (23), p.2189-2197

2012

Volltextzugriff (PDF)

Moving a Pioneer Journal Into the Future

Seminars in oncology, 2016-02, Vol.43 (1), p.1-1

2016

Volltextzugriff (PDF)

MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors

Surgery, 2013-12, Vol.154 (6), p.1224-1229

2013

Volltextzugriff (PDF)

MicroRNA profiling of adrenocortical tumors reveals miR‐483 as a marker of malignancy

Cancer, 2011-04, Vol.117 (8), p.1630-1639

2011

Volltextzugriff (PDF)

The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward

Seminars in oncology, 2022-12, Vol.49 (6), p.427-428

Fojo, Tito

2022

Volltextzugriff (PDF)

Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trials

Clinical trials (London, England), 2021-12, Vol.18 (6), p.690-698

2021

Volltextzugriff (PDF)

CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY

Endocrine practice, 2016-03, Vol.22 (3), p.302-314

2016

Volltextzugriff (PDF)

New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia

Journal of clinical oncology, 2013-05, Vol.31 (13), p.1690-1698

2013

Volltextzugriff (PDF)

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

Clinical cancer research, 2011-02, Vol.17 (4), p.907-917

2011

Volltextzugriff (PDF)

The Role of ABC Transporters in Clinical Practice

The oncologist (Dayton, Ohio), 2003-10, Vol.8 (5), p.411-424

2003

Volltextzugriff (PDF)

Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitment

The Journal of clinical investigation, 2023-10, Vol.133 (20)

2023

Volltextzugriff (PDF)

The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer

The journal of clinical endocrinology and metabolism, 2014-04, Vol.99 (4), p.1291-1297

2014

Volltextzugriff (PDF)

1 – 25 von 241

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(237)
Mit Volltextzugriff
(215)

Publikationsform

Artikel
(241)

Sprache

Englisch
(241)

Erscheinungsjahr

n.n

Thema

Humans
(235)
Science & Technology
(220)
Life Sciences & Biomedicine
(214)
Oncology
(156)
Female
(87)
Biological And Medical Sciences
(77)
Medical Sciences
(72)
Male
(62)
Middle Aged
(53)
Antineoplastic Agents
(51)
Adult
(49)
Pharmacology. Drug Treatments
(48)
Neoplasms - Drug Therapy
(47)
Tumor Cells, Cultured
(43)
Aged
(36)
Antineoplastic Agents - Therapeutic Use
(36)
Treatment Outcome
(36)
Tumors
(35)
Antineoplastic Agents - Pharmacology
(34)
Chemotherapy
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Precision oncology: origins, optimism, and potential

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib

Cancer Drugs in the United States: Justum Pretium—The Just Price

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?

Precision Oncology: A Strategy we were not Ready to Deploy

Strategies for reversing drug resistance

Gefitinib and Erlotinib in Metastatic Non‐Small Cell Lung Cancer: A Meta‐Analysis of Toxicity and Efficacy of Randomized Clinical Trials

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?

Mechanisms of resistance to PARP inhibitors--three and counting

Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Moving a Pioneer Journal Into the Future

MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors

MicroRNA profiling of adrenocortical tumors reveals miR‐483 as a marker of malignancy

The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward

Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trials

CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY

New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

The Role of ABC Transporters in Clinical Practice

Angiopoietin-2 blockade suppresses growth of liver metastases from pancreatic neuroendocrine tumors by promoting T cell recruitment

The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer

Aktive Filter

Suchergebnisse filtern